SIPO1-AD: a Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients with Mild Alzheimer's Disease Dementia
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Siponimod (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Proof of concept
- Acronyms SIPO1-AD
- 17 Oct 2024 New trial record